秘鲁利马引入PCV13后健康携带儿童中的肺炎链球菌血清型与抗生素耐药性
2018年1月至2019年8月在秘鲁利马开展多中心横断面研究,纳入1000名两岁以下健康儿童,采用鼻咽拭子、纸片扩散法、最低抑菌浓度法和全基因组测序检测肺炎链球菌携带、血清型及耐药性。结果显示携带率20.8% vs 引入PCV7前31.1%(p<0.001),PCV13血清型携带从59.1%降至18.7%(p<0.001),但非PCV13血清型和抗生素耐药增加。
要点
- 携带率20.8% vs 引入PCV7前31.1%(p<0.001)
- PCV13血清型携带从59.1%降至18.7%(p<0.001)
- 青霉素耐药(脑膜炎MIC≥0.12)从60.4%升至74.5%(p=0.001)
核心结论
- 秘鲁引入PCV13后肺炎链球菌鼻咽携带率和PCV13血清型频率下降,但非PCV13血清型和抗生素耐药增加。
研究设计与样本
- 2018年1月至2019年8月在秘鲁利马开展多中心横断面研究,纳入1000名两岁以下健康儿童。
- 采用标准微生物学方法检测鼻咽拭子肺炎链球菌,纸片扩散法和最低抑菌浓度法检测抗菌药物敏感性,全基因组测序确定血清型。
- 与2006年至2008年引入PCV7前开展的类似研究(pre-PCV7)进行比较。
主要发现
- 肺炎链球菌携带率为20.8%,引入PCV7前为31.1%(p<0.001)。
- 最常见血清型为15C、19A和6C,分别占12.4%、10.9%和10.9%。
- 引入PCV13后PCV13血清型携带从引入PCV7前的59.1%降至18.7%(p<0.001)。
- 纸片扩散法显示青霉素耐药75.5%、甲氧苄啶/磺胺甲噁唑(TMP/SMX)耐药75.5%、阿奇霉素耐药50.0%。
- 采用脑膜炎MIC折点(MIC≥0.12)时青霉素耐药率从60.4%升至74.5%(p=0.001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determinate the frequency of Streptococcus pneumoniae nasopharyngeal carriers, serotypes and antimicrobial resistance in healthy children in Lima, Peru, post-PCV13 introduction and to compare the results with a similar study conducted between 2006 and 2008 before PCV7 introduction (pre-PCV7). METHODS: A cross-sectional multicenter study was conducted between January 2018 and August 2019 in 1000 healthy children under two years of age. We use standard microbiological methods to determinate S. pneumoniae from nasopharyngeal swab, Kirby Bauer and minimum inhibitory concentration methods to determinate antimicrobial susceptibility and whole genomic sequencing to determinate pneumococcal serotypes. RESULTS: The pneumococcal carriage rate was 20.8 % vs. 31.1 % in pre-PCV7 (p < 0.001). The most frequent serotypes were 15C, 19A and 6C (12.4 %, 10.9 % and 10.9 % respectively). The carriage of PCV13 serotypes after PCV13 introduction decreased from 59.1 % (before PCV7 introduction) to 18.7 % (p < 0.001). Penicillin resistance was 75.5 %, TMP/SMX 75.5 % and azithromycin 50.0 %, using disk diffusion. Penicillin resistance rates using MIC breakpoint for meningitis (MIC ≥ 0.12) increased from 60.4 % to 74.5 % (p = 0.001). CONCLUSION: The introduction of PCV13 in the immunization program in Peru has decreased the pneumococcal nasopharyngeal carriage and the frequency of PCV13 serotypes; however, there has been an increase in non-PCV13 serotypes and antimicrobial resistance.
引用
- Gonzales BE, Mercado EH, Castillo-Tokumori F, et al. Pneumococcal serotypes and antibiotic resistance in healthy carriage children after introduction of PCV13 in Lima, Peru. Vaccine. 2023. PMID: 37270366. doi:10.1016/j.vaccine.2023.05.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。